Cancer-Related Pain Treatment in Birmingham & Bessemer, AL

Cancer Pain Treatment at Alabama Pain Physicians

Cancer pain is different from other pain — and it deserves specialized treatment. Whether your pain is from the cancer itself, chemotherapy side effects, radiation, or surgery, our physicians have the expertise and compassion to help you through it.

Your treatment plan may include:

• Medical management — carefully titrated pain medications including appropriate opioid therapy when needed, adjuvant analgesics, and anti-neuropathic medications
• Nerve blocks — targeted injections to block pain from specific tumor-affected areas
• Celiac plexus and superior hypogastric plexus blocks — for abdominal and pelvic cancer pain
• Intrathecal drug delivery (pain pumps) — delivering medication directly to the spinal fluid for severe pain with fewer systemic side effects
• Spinal cord stimulation — for chemotherapy-induced peripheral neuropathy and post-surgical pain
• Vertebral augmentation — for pathological fractures and vertebral metastases
• Medical marijuana certification — for qualifying cancer patients seeking additional pain and symptom relief

We work closely with your oncologist to ensure your pain treatment supports your overall cancer care. You don't have to suffer through cancer treatment in pain.

Understanding Cancer Pain: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind cancer-related pain. This research informs how we approach cancer pain management at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed patients with cancer-related pain at every stage of their oncologic journey — from the initial diagnosis through active treatment, survivorship, and palliative care. Cancer-related pain is fundamentally different from every other pain condition in this publication series. The disease itself devastates every biological domain. The treatments designed to save the patient’s life — chemotherapy, radiation, immunotherapy, surgery, corticosteroids — create additional domain destruction as an unavoidable consequence of their therapeutic mechanism. And the opioids prescribed to manage the resulting pain produce further domain deterioration through hormonal suppression, metabolic disruption, gut dysfunction, and immune impairment.

This publication does not propose that cellular systems analysis replaces oncologic care. Cancer treatment decisions belong to the oncologist. What this publication proposes is that the biological domains devastated by the disease and its treatment can be evaluated and supported through cellular systems analysis, potentially improving treatment tolerance, reducing pain, preserving functional capacity, and enhancing quality of life alongside standard oncologic management. The cancer patient deserves both — the best oncologic treatment available and the most comprehensive biological support achievable.

These publications are my attempt to provide information about this understanding. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background

Cancer-related pain affects 55% of patients during treatment and 66% in advanced, metastatic, or terminal illness, with 38% reporting moderate to severe pain at all stages of disease (van den Beuken-van Everdingen et al., Journal of Pain and Symptom Management, 2016). Among 17 million US cancer survivors, 31–35% have chronic pain post-therapy (PMC, 2021). Chemotherapy-induced peripheral neuropathy (CIPN) affects approximately 68% of patients in the first month after chemotherapy, with 30% experiencing persistent neuropathy at six months or more (Seretny et al., Pain, 2014). No FDA-approved prevention or treatment for CIPN exists. Cancer cachexia — a syndrome of progressive muscle wasting, weight loss, and systemic inflammation — affects up to 80% of patients with advanced cancer and is directly associated with reduced treatment tolerance, functional decline, and mortality (Fearon et al., Lancet Oncology, 2011). Current pain management relies predominantly on opioids, which produce hormonal suppression, metabolic deterioration, immune impairment, and gut dysfunction that compound the biological devastation of the disease and its treatment.

Methods

We conducted a narrative review of PubMed-indexed literature examining cancer-related pain through cellular systems theory. We reviewed evidence for multi-domain biological dysfunction arising from the cancer itself, its treatment, opioid therapy, and cachexia. We analyzed the pathophysiology of CIPN through a mitochondrial and oxidative stress framework. We examined anabolic failure in cancer cachexia and evidence for hormonal and metabolic interventions. We constructed composite clinical scenarios illustrating individualized domain-targeted supportive care alongside oncologic management.

Results

Published evidence demonstrates that cancer-related pain involves simultaneous domain dysfunction from multiple sources: the tumor itself generates pain through direct tissue invasion, nerve compression, and inflammatory mediator production; chemotherapy destroys mitochondria, damages peripheral nerves, and activates neuroinflammatory cascades through TLR4/NF-κB pathways; cancer cachexia reflects anabolic failure driven by tumor-derived cytokines (TNF-α, IL-6, IL-1β) that overwhelm endogenous anabolic signaling; radiation produces fibrosis through structural domain dysfunction; opioid therapy suppresses the HPA axis, reduces testosterone, disrupts sleep, impairs gut function, and may adversely affect cancer survival; and the psychosocial stress of cancer activates inflammatory and immune-suppressive pathways through HPA axis dysregulation.

Conclusions

Cancer-related pain represents the most extreme multi-domain biological devastation in clinical medicine, with the disease, its treatment, and the management of its symptoms each contributing to progressive domain dysfunction. Cellular systems theory provides a framework for identifying and supporting the specific domains most compromised in each patient, complementing oncologic care with domain-targeted interventions aimed at preserving biological resilience, improving treatment tolerance, and enhancing quality of life.

1. Introduction

Cancer-related pain is unlike any other pain condition. In every other publication in this series — from low back pain to CRPS — the pain arises from the patient’s own biological dysfunction: their metabolic environment, their inflammatory cascade, their hormonal insufficiency. In cancer pain, an additional agent of destruction is present: the tumor itself, actively invading tissue, compressing nerves, co-opting vasculature, secreting cytokines, and commandeering metabolic resources. And unlike any other condition, the treatment for the disease — the chemotherapy, the radiation, the surgery — creates its own domain destruction as a necessary consequence of tumor control.

Pain affects 55% of patients during cancer treatment and 66% in advanced, metastatic, or terminal illness, with 38% reporting moderate to severe pain at all stages of disease (van den Beuken-van Everdingen et al., Journal of Pain and Symptom Management, 2016). Among the approximately 17 million US cancer survivors, 31–35% have chronic pain post-therapy (PMC, 2021). Despite decades of attention to cancer pain management, a recent systematic review concluded that no major advances have been made in the management of cancer pain in 50 years (PMC, 2023). Opioid analgesics remain the cornerstone of moderate to severe cancer pain management, yet approximately 90% of persons with moderate to severe cancer pain can achieve adequate control with opioids (ASCO, 2023). The challenge is not whether opioids work for cancer pain — they do. The challenge is the biological cost of opioid therapy in a patient whose biological domains are already devastated by the disease and its treatment.

Cellular systems theory proposes that cancer-related pain can be understood through the same multi-domain framework applied throughout this publication series, with two critical differences. First, the domains are being assaulted from multiple directions simultaneously — by the disease, by the treatment, by the opioids, by the deconditioning, by the psychological burden. Second, the goal is not to correct the disease biology (that is the oncologist’s domain) but to support the patient’s biological resilience — to preserve the metabolic, mitochondrial, hormonal, immune, and gut domains so that the patient can tolerate treatment better, recover more completely, maintain functional capacity, and experience less pain.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining cancer-related pain through cellular systems theory. Search terms included cancer pain, chemotherapy-induced peripheral neuropathy, CIPN, cancer cachexia, radiation fibrosis combined with mitochondrial dysfunction, oxidative stress, neuroinflammation, TLR4, NF-κB, opioid side effects, hypogonadism, HPA axis, gut microbiome, anabolic, testosterone, growth hormone, muscle wasting, sarcopenia, treatment tolerance, quality of life, and palliative optimization. We included systematic reviews, meta-analyses, randomized controlled trials, mechanistic studies, and clinical guidelines. We constructed composite clinical scenarios illustrating individualized domain-targeted supportive care alongside oncologic management.

3. The Multiple Sources of Cancer-Related Pain

3.1 Tumor-Related Pain

Tumors generate pain through direct invasion of bone, nerve, and visceral structures; compression of adjacent nerves and vascular structures; distension of organ capsules; and production of inflammatory and algesic mediators. Bone metastases, present in up to 70% of patients with breast and prostate cancer, produce pain through osteoclast-mediated bone destruction, periosteal stretching, and pathological fracture (NCI PDQ, 2025). Tumor-secreted cytokines including TNF-α, IL-6, and IL-1β sensitize peripheral nociceptors and contribute to both local and systemic inflammatory pain. Nerve compression by tumor produces neuropathic pain with burning, shooting, and allodynic features. Visceral invasion produces poorly localized, deep, aching pain through activation of visceral afferents that converge on the same spinal pathways described in the companion pelvic pain publication (Thomas, Alabama Pain Physicians, 2026).

3.2 Chemotherapy-Induced Peripheral Neuropathy

CIPN is the most significant treatment-related pain syndrome in oncology. It affects approximately 68% of patients in the first month after chemotherapy, 60% at three months, and 30% at six months or more (Seretny et al., Pain, 2014). CIPN prevalence varies from 19% to 85% depending on the agent and dose (Frontiers in Molecular Neuroscience, 2024). Platinum agents are the most neurotoxic, with oxaliplatin causing the highest prevalence. CIPN can worsen after treatment cessation — a phenomenon known as “coasting” — and approximately 30% of patients have persistent neuropathy one year or more after completing chemotherapy (PMC, 2019). Severe CIPN may require dose reduction or cessation of chemotherapy, directly impacting cancer survival (Cancers, 2024).

The pathophysiology of CIPN involves simultaneous dysfunction across multiple biological mechanisms: mitochondrial dysfunction and oxidative stress are implicated as key mechanisms (PubMed, 2013; Frontiers in Molecular Neuroscience, 2024); direct mitochondrial DNA damage contributes to cisplatin-induced CIPN (Podratz et al., 2011); microtubule disruption damages axonal transport (taxanes, vinca alkaloids); ion channel impairment alters neuronal excitability; and neuroinflammation through immune cell activation — including Langerhans cell invasion into the epidermis and mast cell activation through TLR4 pathways — degenerates intraepidermal nerve fibers (Frontiers in Molecular Neuroscience, 2024). Critically, the gut microbiota has been implicated in oxaliplatin-induced neuropathy through TNF-α, IL-6, and LPS-TLR4 pathways (Anticancer Research, 2022), connecting the gut domain directly to CIPN pathophysiology.

No FDA-approved prevention or treatment for CIPN exists. Duloxetine is the only agent with Level I evidence for established CIPN (ASCO guidelines). Many oral medications commonly used for CIPN — opioids, antidepressants, antiepileptics — are not supported by randomized studies specific to CIPN (PMC, 2023). The mitochondrial dysfunction at the core of CIPN pathophysiology suggests that mitochondrial-targeted interventions could address the mechanism rather than the symptom.

3.3 Cancer Cachexia: The Anabolic Catastrophe

Cancer cachexia is a multi-organ syndrome characterized by progressive skeletal muscle loss (with or without fat loss) that cannot be fully reversed by conventional nutritional support (Fearon et al., Lancet Oncology, 2011). It affects up to 80% of patients with advanced cancer and is directly responsible for an estimated 20–30% of cancer deaths (Tisdale, Nature Reviews Cancer, 2002). Cachexia is not starvation. It is a fundamentally different metabolic state in which the tumor drives catabolic processes through systemic inflammation while simultaneously suppressing anabolic signaling.

The catabolic drive in cachexia is mediated by tumor-derived and host-derived inflammatory cytokines — TNF-α (originally named “cachexin” for its role in wasting), IL-6, IL-1β, and interferon-gamma — that activate the ubiquitin-proteasome pathway in skeletal muscle, accelerating protein degradation (Argilés et al., Nature Reviews Cancer, 2014). Simultaneously, NF-κB activation in muscle tissue directly promotes muscle wasting through increased atrogin-1 and MuRF1 expression (Cai et al., Cell, 2004). Proteolysis-inducing factor (PIF), produced by tumors, directly degrades muscle protein through the ubiquitin-proteasome system (Lorite et al., British Journal of Cancer, 2001). Myostatin — a negative regulator of muscle growth — is upregulated in cancer cachexia, further suppressing the anabolic pathways needed to counter muscle loss (Costelli et al., European Journal of Clinical Investigation, 2008).

The anabolic failure in cachexia extends beyond muscle. Growth hormone resistance develops, with GH levels often normal or elevated but IGF-1 levels reduced — reflecting hepatic resistance to GH signaling driven by inflammation (Costelli et al., 2008). Testosterone levels decline from both the catabolic state and the opioid-induced hypogonadism that accompanies pain management. Insulin resistance develops, impairing glucose utilization by muscle tissue while the tumor preferentially consumes glucose through aerobic glycolysis (the Warburg effect). The net result is a patient who cannot build muscle, cannot maintain weight, cannot tolerate chemotherapy doses, and cannot recover from treatment cycles — not because they are not eating, but because their anabolic signaling is overwhelmed by the catabolic drive.

Conventional nutritional support fails in cachexia because the problem is not caloric deficit but anabolic signaling failure. You cannot feed your way out of cachexia any more than you can exercise your way out of a testosterone deficiency. The metabolic and hormonal machinery required to convert nutrition into muscle protein is suppressed. Restoring anabolic capacity through testosterone optimization, growth hormone axis support, and metabolic interventions that target AMPK activation and insulin sensitization represents domain-targeted treatment for the neuroendocrine and metabolic catastrophe that cachexia produces. This approach requires close coordination with the oncology team, as growth hormone and androgen axis stimulation must be evaluated in the context of each patient’s specific tumor biology.

3.4 Radiation-Related Pain and Fibrosis

Radiation therapy produces acute inflammatory pain during and immediately after treatment, followed by chronic fibrotic changes that develop over months to years. Radiation fibrosis affects skin, subcutaneous tissue, muscle, nerve, and vascular structures in the radiation field, producing progressive pain, stiffness, and functional impairment. Radiation plexopathy — nerve damage in the brachial or lumbosacral plexus from radiation fibrosis — can produce severe neuropathic pain that is often difficult to distinguish from tumor recurrence. Radiation fibrosis represents structural domain dysfunction — dysregulated wound healing producing excessive collagen deposition and tissue contraction rather than normal repair.

3.5 The Opioid Burden in Cancer Pain

Opioids are necessary and appropriate for moderate to severe cancer pain. This is not in dispute. However, the biological cost of chronic opioid therapy is particularly devastating in the cancer patient because it compounds the domain destruction already produced by the disease and its treatment. Opioid-induced hypogonadism affects up to 75% of men on chronic opioid therapy, reducing the testosterone needed for muscle maintenance in a patient already losing muscle to cachexia. Opioid-induced HPA axis suppression reduces the cortisol response needed for stress adaptation and inflammatory regulation (Heim et al., Psychoneuroendocrinology, 2000). Opioid-induced gut dysfunction damages the microbiome in a patient whose gut is already compromised by chemotherapy-induced mucositis. Opioid-induced sleep disruption impairs the restorative sleep needed for immune function and tissue repair. Opioid-induced immune suppression further compromises an immune system already devastated by chemotherapy and the tumor itself.

Cancer-related pain and opioid requirements are associated with poor survival in advanced cancer patients. Postoperative opioid use may have adverse effects on cancer survival (PubMed, 2020). The prevalence of opioid use disorder in cancer patients is approximately 8%, with the risk of misuse estimated at 23.5% (PMC, 2022). The cancer patient on chronic opioids represents the most extreme domain devastation in clinical medicine: every biological system relevant to survival, recovery, and quality of life is under simultaneous assault from the disease, the treatment, and the pain management.

4. Domain Analysis: The Convergence of Destruction

4.1 Mitochondrial and Metabolic Domain

The mitochondrial domain is ground zero for CIPN. Chemotherapy agents damage mitochondrial DNA, disrupt electron transport chain function, and generate oxidative stress that degrades peripheral nerve fibers (PubMed, 2013). The tumor itself disrupts host metabolism through the Warburg effect, competing for glucose and producing lactate that acidifies the microenvironment. Cachexia produces insulin resistance that impairs muscle glucose utilization. Corticosteroids used for nausea, inflammation, and pain management worsen insulin resistance. The metabolic domain in the cancer patient is assaulted from every direction simultaneously.

4.2 Immune Domain

Cancer produces immune exhaustion — T-cell dysfunction, NK cell impairment, and regulatory T-cell overactivation that allows the tumor to evade immune surveillance. Chemotherapy produces iatrogenic immunosuppression through bone marrow toxicity. Opioids further suppress immune function through direct effects on immune cells. Radiation damages local immune tissue. The result is a patient with profound immune compromise whose immune system cannot fight the tumor, cannot resolve inflammation, and cannot protect against infection — yet who may benefit from immune checkpoint inhibitors that require functional immune capacity to be effective. Supporting immune resilience through domain-targeted interventions could potentially enhance the effectiveness of immunotherapy while reducing the infectious complications of immunosuppression.

4.3 Neuroendocrine Domain: The Anabolic Collapse

Cancer cachexia, opioid therapy, corticosteroid use, and the psychological stress of the disease converge on the neuroendocrine domain to produce comprehensive hormonal devastation. Testosterone declines from opioid suppression, catabolic cytokine effects, and sometimes from androgen deprivation therapy for prostate cancer. Growth hormone signaling becomes resistant from hepatic inflammation. DHEA-S and adrenal androgens decline. Thyroid function is altered by the sick-euthyroid syndrome. HPA axis dysregulation from chronic stress produces cortisol abnormalities. Sleep disruption from pain, anxiety, and opioid effects reduces growth hormone release during deep sleep. This neuroendocrine collapse removes every anabolic pathway needed for muscle maintenance, tissue repair, immune function, and pain modulation.

Restoring anabolic signaling is not an optional adjunct — it is a direct treatment for the neuroendocrine domain dysfunction driving cachexia, deconditioning, and treatment intolerance. Testosterone replacement in hypogonadal cancer patients improves lean mass, fatigue, and quality of life (Del Fabbro et al., Journal of Clinical Oncology, 2013; Garcia et al., Journal of Clinical Endocrinology and Metabolism, 2015). Growth hormone secretagogues including anamorelin (a ghrelin receptor agonist) have demonstrated improvement in lean body mass in cancer cachexia in Phase III trials (Temel et al., Lancet Oncology, 2016). These interventions address the anabolic signaling failure directly, restoring the biological capacity to convert nutrition into functional tissue. Hormonal optimization in cancer patients requires close oncologic coordination to ensure compatibility with the specific tumor biology and treatment plan.

4.4 Microbiome Domain

Chemotherapy produces mucositis — direct damage to the gastrointestinal mucosa — that disrupts the gut barrier and alters microbiome composition. The resulting dysbiosis reduces nutrient absorption, impairs immune function, and drives systemic inflammation through LPS translocation and NF-κB activation (Camilleri, Gut, 2019). Opioid-induced constipation further alters the gut microbiome. Antibiotic use during neutropenic episodes depletes beneficial organisms. The gut microbiota has been directly implicated in CIPN development through TNF-α, IL-6, and LPS-TLR4 pathways for oxaliplatin (Anticancer Research, 2022). Supporting gut barrier integrity and microbiome diversity during and after chemotherapy could potentially reduce CIPN severity and systemic inflammatory burden.

4.5 Psychological Domain

Major depressive disorder is up to four times more prevalent among cancer patients than in the general population (PMC, 2022). The psychosocial stress of cancer increases inflammation, promotes oxidative stress, depresses the immune system, and activates dysfunctional HPA axis and autonomic nervous system responses (PMC, 2022). Sleep disruption is nearly universal in cancer patients, impairing immune function, tissue repair, and pain modulation. Anxiety and cancer-related distress amplify central sensitization, lowering pain thresholds and increasing opioid requirements. Addressing the psychological domain through non-sedating anxiolytics, sleep restoration, and stress-axis modulation directly supports pain management and biological resilience.

5. Inter-Domain Cascade Mechanics in Cancer Pain

5.1 The Chemotherapy-Mitochondrial-Neural Cascade (CIPN)

Chemotherapy agents (platinum compounds, taxanes, vinca alkaloids, bortezomib) damage mitochondrial DNA and disrupt electron transport chain function in dorsal root ganglion neurons. Impaired mitochondrial bioenergetics produce reactive oxygen species that overwhelm antioxidant defenses. ROS damage intraepidermal nerve fibers (IENF), producing the “stocking and glove” sensory loss and pain characteristic of CIPN. Neuroinflammation through glial cell activation and Langerhans cell invasion into the epidermis amplifies nerve fiber degeneration (Frontiers in Molecular Neuroscience, 2024). The gut microbiota contributes through LPS-TLR4 inflammatory signaling. The cascade is self-sustaining: mitochondrial dysfunction generates ROS, ROS generate neuroinflammation, neuroinflammation generates further mitochondrial damage. CIPN “coasting” — worsening after chemotherapy cessation — reflects this self-sustaining cascade continuing after the chemotherapy trigger is removed.

5.2 The Catabolic-Anabolic Imbalance Cascade (Cachexia)

Tumor-derived TNF-α, IL-6, and IL-1β activate the ubiquitin-proteasome pathway in skeletal muscle (Argilés et al., 2014). NF-κB activation in muscle directly promotes proteolysis through atrogin-1 and MuRF1 upregulation (Cai et al., 2004). Myostatin upregulation suppresses satellite cell activation and muscle regeneration (Costelli et al., 2008). Simultaneously, anabolic signaling collapses: testosterone falls from opioids and cytokine effects. Growth hormone resistance develops from hepatic inflammation. Insulin resistance impairs muscle glucose uptake. The catabolic drive exceeds the anabolic capacity, producing net muscle loss regardless of nutritional intake. Deconditioning from pain, fatigue, and weakness further reduces the mechanical stimulus for muscle maintenance. Muscle loss increases insulin resistance (muscle is the primary tissue for glucose disposal), creating a self-amplifying metabolic spiral. Conventional caloric supplementation addresses the substrate without addressing the machinery. Anabolic restoration — testosterone, growth hormone axis optimization, AMPK activation — addresses the machinery.

5.3 The Treatment-Opioid-Domain Devastation Cascade

Chemotherapy damages the gut and nerves. Pain from the disease and the treatment necessitates opioids. Opioids suppress testosterone, cortisol, and growth hormone. Hormonal depletion worsens cachexia and impairs immune function. Opioid-induced constipation worsens the gut already damaged by chemotherapy. Immune suppression from opioids compounds the immunosuppression from chemotherapy. Deconditioning from opioid sedation and pain-limited activity worsens metabolic and structural domains. Each treatment layer addresses one problem while creating or worsening another. The cancer patient accumulates domain insults from the disease, from each treatment modality, and from each medication, producing a progressive biological deterioration that accelerates with each treatment cycle.

6. Clinical Scenarios: Individualized Domain-Targeted Supportive Care

The following composite clinical scenarios illustrate how cellular systems theory guides domain-targeted supportive care alongside oncologic management. All laboratory values represent plausible clinical findings. All interventions are intended to complement, not replace, oncologic treatment.

6.1 Patient A: CIPN During Active Chemotherapy

Presentation: 58-year-old woman receiving oxaliplatin-based FOLFOX chemotherapy for stage III colon cancer. After cycle 8 of 12, she has developed progressive numbness and burning pain in both hands and feet (CIPN grade 2). Oncologist is considering dose reduction, which would compromise tumor response. Reports fatigue 8/10, poor sleep, and anxiety about losing function. Pain 6/10 in hands and feet. Currently taking gabapentin 600 mg TID with modest benefit and significant drowsiness.

Domain Assessment — Laboratory Findings: Fasting insulin 14 µIU/mL (mildly elevated). Vitamin D 16 ng/mL (deficient). Omega-3 index 2.0% (critically low). RBC magnesium low. Vitamin B12 low-normal. Organic acids showing markers consistent with mitochondrial dysfunction and elevated 8-OHdG (oxidative DNA damage). hs-CRP 4.2 mg/L (elevated). Microbiome analysis showing reduced diversity with depleted Lactobacillus (consistent with chemo-induced dysbiosis).

Domain Interpretation: This patient demonstrates the chemotherapy-mitochondrial-neural cascade. Mitochondrial dysfunction markers confirm the mechanism driving her CIPN. Critically deficient vitamin D, omega-3, and magnesium remove neuroprotective substrates. Gut dysbiosis may be amplifying CIPN through the LPS-TLR4 pathway documented for oxaliplatin. Gabapentin addresses calcium channel modulation without addressing mitochondrial damage, oxidative stress, or neuroinflammation. Dose reduction is clinically reasonable but comes at the cost of potentially reduced tumor response. Domain-targeted support may preserve nerve function enough to complete the chemotherapy course.

Individualized Protocol (alongside continued oncologic management): SS-31 (5–10 mg SC daily) for mitochondrial membrane stabilization targeting the core mechanism of CIPN (Szeto, British Journal of Pharmacology, 2014; Birk et al., JASN, 2013). NAD+ (IV 250–500 mg 1–2x weekly) for mitochondrial energy substrate. Glutathione (IV 600–1200 mg 1–2x weekly) for antioxidant defense against ROS. Vitamin D repletion urgently. Omega-3 repletion. Magnesium repletion (glycinate form). B12 optimization (methylcobalamin). BPC-157 (250–500 µg orally twice daily) for gut barrier support during chemotherapy and nerve repair potential (Gwyer et al., Cell and Tissue Research, 2019; Gjurasin et al., Regulatory Peptides, 2010). MOTS-c (5–10 mg SC three times weekly) for AMPK activation paralleling metformin’s documented anti-CIPN mechanism (Lee et al., Cell Metabolism, 2015). DSIP (100–200 µg SC at bedtime) for sleep restoration. Reassessment of CIPN grade, mitochondrial markers, and neuropathy symptoms at 4 weeks to inform chemotherapy dosing decision.

6.2 Patient B: Cancer Cachexia with Opioid-Induced Anabolic Collapse

Presentation: 66-year-old man with stage IV non-small cell lung cancer. Lost 28 pounds (18% body weight) over 6 months. BMI dropped from 27 to 22. Severe fatigue, unable to complete daily activities. Reports poor appetite despite nutritional supplements. On morphine ER 60 mg BID plus oxycodone for breakthrough. Caloric intake adequate per dietary assessment. Progressive weakness and muscle wasting. Pain 5/10 (controlled on opioids). Oncologist reports he is not tolerating immunotherapy well and considering discontinuation.

Domain Assessment — Laboratory Findings: Total testosterone 98 ng/dL (critically low; reference 300–900). Free testosterone undetectable. DHEA-S undetectable. Morning cortisol 3.2 µg/dL (profoundly suppressed). IGF-1 low (growth hormone resistance). Albumin 2.9 g/dL (low). Prealbumin 12 mg/dL (depleted). hs-CRP 14.2 mg/L (markedly elevated). Fasting insulin 18 µIU/mL (elevated — insulin resistance despite weight loss). Vitamin D 11 ng/mL (severely deficient). Hemoglobin 10.2 g/dL (anemia of chronic disease).

Domain Interpretation: This patient demonstrates the catabolic-anabolic imbalance cascade. Despite adequate caloric intake, he continues to lose weight because the anabolic signaling machinery is destroyed. Critically low testosterone from opioid suppression removes the primary anabolic hormone for muscle maintenance. Undetectable DHEA-S and suppressed cortisol reflect complete HPA axis devastation. Low IGF-1 despite probable GH resistance confirms neuroendocrine domain collapse. Markedly elevated hs-CRP confirms the inflammatory catabolic drive. Insulin resistance paradoxically coexists with weight loss because the tumor-driven inflammatory state impairs insulin signaling. Nutritional supplements fail because the body cannot process nutrients into functional tissue without anabolic hormonal support. His poor immunotherapy tolerance may partly reflect the biological devastation impairing immune function.

Individualized Protocol (alongside oncologic management, with oncologist coordination): Testosterone replacement (200 mg IM every 2 weeks or transdermal) guided by oncologic assessment of tumor hormone sensitivity — not contraindicated in non-hormone-sensitive cancers (Del Fabbro et al., Journal of Clinical Oncology, 2013; Garcia et al., Journal of Clinical Endocrinology and Metabolism, 2015). Ipamorelin/CJC-1295 at bedtime for growth hormone secretagogue support — requires oncologic assessment of IGF-1 axis in the context of specific tumor biology. DHEA replacement guided by endocrine assessment. Vitamin D repletion urgently. MOTS-c (5–10 mg SC three times weekly) for metabolic optimization and insulin sensitization (Lee et al., 2015). BPC-157 (250–500 µg orally twice daily) for gut barrier support during opioid-related gut compromise (Gwyer et al., 2019). GHK-Cu (1–2 mg SC daily) for tissue repair gene expression modulation (Pickart and Margolina, 2014; Pickart et al., 2018). Thymosin Alpha-1 (1.6 mg SC twice weekly) for immune support alongside immunotherapy. KPV (200–400 µg orally twice daily) for NF-κB inhibition targeting the catabolic inflammatory drive. Resistance exercise program as tolerated — even minimal resistance provides mechanical stimulus for muscle protein synthesis when anabolic signaling is restored. Graded opioid optimization targeting the minimum effective dose. Reassessment at 8 weeks.

6.3 Patient C: Cancer Survivorship Chronic Pain

Presentation: 52-year-old woman, 2 years post-treatment for stage II breast cancer (mastectomy, adjuvant chemotherapy with docetaxel, radiation). Cancer-free on surveillance. Persistent bilateral hand and foot numbness and burning (CIPN). Chronic chest wall pain at mastectomy site. Radiation fibrosis in the left axilla with restricted shoulder range of motion. Reports fatigue, weight gain of 22 pounds since treatment, poor sleep, and anxiety about recurrence. On tamoxifen. Pain 5/10 in hands/feet, 4/10 chest wall. Has been told her pain is “a normal side effect” and offered gabapentin.

Domain Assessment — Laboratory Findings: Fasting insulin 20 µIU/mL (elevated). HbA1c 6.1% (prediabetic). hs-CRP 3.6 mg/L (elevated). Vitamin D 20 ng/mL (deficient). Omega-3 index 2.4% (critically low). Organic acids showing persistent mitochondrial dysfunction markers. Elevated evening cortisol (HPA overactivation). Microbiome showing reduced diversity.

Domain Interpretation: This cancer survivor demonstrates persistent multi-domain dysfunction two years after treatment completion. CIPN has not resolved because the mitochondrial damage is self-sustaining and the neuroprotective substrates (vitamin D, omega-3, B vitamins) have never been repleted. Post-treatment metabolic syndrome has developed — weight gain from deconditioning and tamoxifen effects, insulin resistance, and systemic inflammation — creating a metabolic environment that impairs nerve repair and maintains the inflammatory tone feeding persistent CIPN. Chest wall pain reflects post-surgical neuropathic changes. Radiation fibrosis represents structural domain dysfunction. The survivorship paradigm of surveillance and tamoxifen without biological domain assessment leaves this patient in a chronic state of multi-domain dysfunction that is amenable to intervention.

Individualized Protocol: Metabolic optimization: anti-inflammatory dietary protocol, graded exercise program targeting insulin sensitization and deconditioning reversal. SS-31 (5–10 mg SC daily) for persistent mitochondrial dysfunction (Szeto, 2014). Vitamin D repletion. Omega-3 repletion. BPC-157 (250–500 µg SC and orally) for nerve repair and gut barrier (Gwyer et al., 2019; Gjurasin et al., 2010). TB-500 (750 µg to 1.5 mg SC twice weekly) for anti-fibrotic tissue remodeling targeting radiation fibrosis (Malinda et al., 1999). GHK-Cu (1–2 mg SC daily) for tissue repair gene expression (Pickart et al., 2018). MOTS-c (5–10 mg SC three times weekly) for metabolic optimization (Lee et al., 2015). Selank (250–500 µg SC two to three times daily) for recurrence anxiety and HPA modulation (Zozulia et al., 2008). DSIP (100–200 µg SC at bedtime) for sleep restoration. Physical therapy for radiation fibrosis and chest wall rehabilitation. Medical cannabis evaluation (mythcdr.com, $150) for neuropathic pain modulation. Reassessment at 12 weeks.

7. Emerging Peptide Therapeutics: Domain-Targeted Supportive Care

Peptide therapeutics offer potential for domain-targeted supportive care in cancer-related pain. No RCTs of these peptides for cancer pain as primary indications have been published. All are intended as adjuncts to oncologic management, not as cancer treatments.

SS-31 (elamipretide) stabilizes the inner mitochondrial membrane by binding cardiolipin, improving bioenergetic efficiency and reducing ROS generation (Szeto, 2014; Birk et al., 2013; Karaa et al., Neurology, 2018). Its mechanism directly targets the mitochondrial dysfunction identified as a key driver of CIPN. Subcutaneously at 5–10 mg daily. Not FDA-approved for CIPN.

BPC-157 has demonstrated nerve regeneration in preclinical models (Gjurasin et al., 2010; Perovic et al., 2019), restores gut barrier integrity (relevant to chemotherapy-induced mucositis), and restores nitric oxide production (Gwyer et al., 2019). Its combined nerve repair, gut protection, and vascular support address three domains simultaneously damaged by cancer treatment. Orally at 250–500 µg twice daily. Not FDA-approved.

MOTS-c activates AMPK to improve insulin sensitivity and reduce inflammatory cytokines (Lee et al., 2015). Its AMPK activation parallels metformin’s documented efficacy in reducing CIPN and improving insulin sensitivity in cancer patients. Subcutaneously at 5–10 mg three times weekly. Not FDA-approved.

Thymosin Alpha-1 rebalances immune function by restoring Th1/Th2 balance, activating dendritic cells, and enhancing NK cell function. Approved in over 35 countries for immune support in cancer and hepatitis. Its immune rebalancing rather than immunosuppression makes it potentially compatible with immunotherapy protocols. Subcutaneously at 1.6 mg two to three times weekly. Not FDA-approved in the US.

TB-500 promotes anti-fibrotic tissue remodeling (Malinda et al., 1999). Specifically relevant for radiation fibrosis, which represents structural domain dysfunction amenable to anti-fibrotic intervention. Subcutaneously at 750 µg to 1.5 mg twice weekly. Not FDA-approved.

GHK-Cu stimulates collagen and glycosaminoglycan production and modulates approximately 32% of human gene expression toward repair patterns (Pickart and Margolina, 2014; Pickart et al., 2018). Its capacity to reset gene expression toward tissue repair is relevant for the widespread tissue damage from cancer treatment. Subcutaneously at 1–2 mg daily. Not FDA-approved.

Ipamorelin/CJC-1295 stimulates endogenous growth hormone release through the ghrelin receptor and GHRH receptor respectively. Relevant to cancer cachexia as growth hormone secretagogue support, paralleling the Phase III evidence for anamorelin (ghrelin receptor agonist) improving lean body mass in cachexia (Temel et al., Lancet Oncology, 2016). Requires oncologic assessment of the IGF-1 axis in the context of specific tumor biology. Subcutaneously at bedtime. Not FDA-approved.

KPV directly inhibits NF-κB without immunosuppression. Targets the NF-κB-mediated catabolic signaling driving cachexia (Cai et al., 2004) and the NF-κB-mediated neuroinflammation contributing to CIPN. Orally at 200–400 µg twice daily. Not FDA-approved.

Peptide selection is guided by domain assessment and must be coordinated with the oncology team. The critical principle is that these interventions support biological resilience without interfering with tumor-directed therapy.

8. Discussion

The evidence reviewed in this paper supports three propositions. First, cancer-related pain involves simultaneous domain destruction from multiple sources — the tumor, the treatment, the opioids, the deconditioning, and the psychological burden — that converge to produce the most extreme multi-domain biological devastation in clinical medicine. CIPN is a mitochondrial and oxidative stress disorder. Cachexia is an anabolic signaling failure. Radiation fibrosis is a structural repair disorder. Opioid-induced hormonal, metabolic, and gut dysfunction compounds every domain insult.

Second, the conventional approach of managing cancer pain primarily through opioid titration, while oncologically appropriate, produces progressive domain deterioration that worsens cachexia, impairs immune function, disrupts the gut, suppresses hormonal axes, and may adversely affect survival. Supporting the biological domains devastated by disease and treatment is not a luxury — it is a clinical necessity for patients who need to maintain the biological capacity to tolerate treatment, recover from treatment cycles, and preserve functional independence.

Third, cancer cachexia illustrates the limits of single-domain thinking most clearly. Caloric supplementation fails because the problem is not energy input but anabolic signaling capacity. The catabolic drive from tumor-derived cytokines overwhelms endogenous anabolic pathways. Restoring anabolic capacity through testosterone, growth hormone axis support, and metabolic optimization addresses the domain-level dysfunction that nutritional support alone cannot overcome. Phase III evidence for anamorelin (Temel et al., 2016) and clinical evidence for testosterone in cancer hypogonadism (Del Fabbro et al., 2013; Garcia et al., 2015) demonstrate that hormonal domain restoration improves lean body mass and quality of life in cancer patients.

Limitations include the narrative methodology, the preclinical basis of most peptide evidence for cancer-specific indications, the critical importance of oncologic coordination for hormonal and growth factor interventions, the absence of randomized trials testing multi-domain supportive care protocols in cancer pain, and the heterogeneity of cancer populations. Prospective trials evaluating domain-targeted supportive care alongside standard oncologic management are needed.

9. Conclusion

Cancer-related pain is the product of simultaneous biological destruction from the disease, its treatment, and the medications used to manage its symptoms. The cancer patient does not have one domain problem — they have every domain problem. CIPN is a mitochondrial disorder that current treatments cannot prevent or reverse. Cachexia is an anabolic failure that calories cannot fix. Radiation fibrosis is a structural repair failure. Opioid-induced hormonal, metabolic, and gut dysfunction compounds every domain insult from every other source. Cellular systems theory provides a framework for identifying which domains are most compromised in each cancer patient and directing supportive interventions accordingly — restoring mitochondrial function for CIPN, restoring anabolic capacity for cachexia, restoring gut integrity during chemotherapy, and modulating the hormonal, sleep, and psychological domains that determine biological resilience. The cancer patient deserves both the best oncologic treatment available and the most comprehensive biological support achievable. At Alabama Pain Physicians, we work alongside your oncology team to provide that support.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management. Contact: 205.332.3160. BamaPain.com. For medical cannabis evaluation: mythcdr.com. For opioid recovery services: TheRenewClinic.com.

Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels and peptide therapeutics described in this review as clinical services. No external funding was received for this work.

References

1. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070-1090.

2. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470.

3. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-495.

4. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862-871.

5. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754-762.

6. Cai D, Frantz JD, Tawa NE Jr, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285-298.

7. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer. 2001;85(2):297-302.

8. Costelli P, Muscaritoli M, Bossola M, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006;291(3):R674-R683.

9. Del Fabbro E, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer. 2013;21(9):2599-2607.

10. Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer. 2015;121(14):2306-2314.

11. Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519-531.

12. Pathobiology of CIPN. PubMed. 2013.

13. Current understanding of the molecular mechanisms of CIPN. Frontiers in Molecular Neuroscience. 2024;17:1345811.

14. CIPN: epidemiology, pathomechanisms and treatment. Oncology and Therapy. 2021.

15. Clinical and preclinical perspectives on CIPN. PubMed. 2017.

16. CIPN: where are we now? PMC. 2019.

17. CIPN: a recent update on pathophysiology and treatment. Life. 2024;14(8):991.

18. CIPN: a narrative review and proposed theoretical model. Cancers. 2024;16(14):2571.

19. Pathophysiology and therapeutic perspectives for CIPN. Anticancer Research. 2022;42(10):4667.

20. Opioid therapy in cancer patients and survivors at risk of addiction. PMC. 2022.

21. Prevalence of opioid use disorder among patients with cancer-related pain. PMC. 2022.

22. Impact of pain and opioids use on survival in cancer patients. PubMed. 2020.

23. Revisiting patient-related barriers to cancer pain management. PMC. 2021.

24. Update on prevalence of pain in patients with cancer 2022. PMC. 2023.

25. ASCO guideline: use of opioids for adults with pain from cancer or cancer treatment. J Clin Oncol. 2023.

26. Cancer pain (PDQ). National Cancer Institute. 2025.

27. Heim C, et al. Hypocortisolism in stress-related disorders. Psychoneuroendocrinology. 2000;25(1):1-35.

28. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

29. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015;21(3):443-454.

30. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell and Tissue Research. 2019;377(2):153-159.

31. Gjurasin M, et al. BPC 157 in traumatic nerve injury. Regulatory Peptides. 2010;160(1-3):33-41.

32. Perovic D, et al. BPC 157 in spinal cord injury. J Orthop Surg Res. 2019;14(1):199.

33. Szeto HH. Cardiolipin-protective compound. Br J Pharmacol. 2014;171(8):2029-2050.

34. Birk AV, et al. SS-31 re-energizes mitochondria. JASN. 2013;24(8):1250-1261.

35. Karaa A, et al. Elamipretide in mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.

36. Malinda KM, et al. Thymosin beta4 in wound healing. J Invest Dermatol. 1999;113(3):364-368.

37. Pickart L, Margolina A. GHK and DNA: resetting the genome. BioMed Res Int. 2014;2014:151479.

38. Pickart L, et al. GHK-Cu regenerative actions. Int J Mol Sci. 2018;19(7):1987.

39. Zozulia AA, et al. Selank in generalized anxiety. Zh Nevrol Psikhiatr. 2008;108(4):38-48.

40. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB Journal. 2008;22(10):3432-3442.

41. Woolf CJ. Central sensitization. Pain. 2011;152(3 Suppl):S2-S15.

42. Watkins LR, Maier SF. Immune and glial cells in pathological pain. Physiological Reviews. 2002;82(4):981-1011.

43. Finan PH, et al. Sleep and pain association. Journal of Pain. 2013;14(12):1539-1552.

44. Choy EH. Sleep in pain and fibromyalgia. Nature Reviews Rheumatology. 2015;11(9):513-520.

45. Helde-Frankling M, et al. Vitamin D in pain management. IJMS. 2017;18(10):2170.

© 2026 Alabama Pain Physicians. All rights reserved.